Drugs / SHR-9539
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT06484777 | Aug 2024 → Jul 2027 expected | plasma cell myeloma | Suzhou Suncadia Biopharmaceuticals Co., Ltd. | Recruiting | No outcome recorded |
Evidence & citations 1 cited value
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | SHR-9539 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT06484777 ↗ |